From May 1, 2023 to July 31, 2023, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 1,883,346 shares, representing 10.34% for $5.63 million under the buyback announced on February 2, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 USD | +3.48% |
|
-0.48% | -3.70% |
17/06 | MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc. | CI |
23/05 | MyMD Pharmaceuticals, Inc. amended terms of the transaction | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.70% | 16.99M | |
+55.95% | 811B | |
+43.62% | 640B | |
-6.98% | 353B | |
+19.08% | 333B | |
+9.05% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.91% | 168B |
- Stock Market
- Equities
- PMCB Stock
- News PharmaCyte Biotech, Inc.
- Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.